Beckman Coulter Announces Release of Three New Work Cells

Beckman Coulter (NYSE:BEC), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, announced today that it has launched three new systems, completing the company's family of integrated chemistry-immunoassay work cells. The new systems range from high volume to very high volume: UniCel DxC 660i Synchron® Access® Clinical System, UniCel DxC 680i, and UniCel DxC 860i.

Every one of the five integrated systems—each targeted to a different test mix and volume—allow laboratories to perform both chemistry and immunoassay testing simultaneously from a single sample with a single point of entry. According to Scott Atkin, group vice president of Beckman Coulter's Chemistry and Clinical Lab Automation business group, "We've used our industry-leading systems integration capability to deliver a range of systems which offer labs tremendous flexibility in addressing their needs. Our work cells have the potential to enhance hospital efficiency by increasing lab productivity, improving patient health and reducing the cost of care."

UniCel DxC chemistry systems or UniCel DxI immunoassay systems already installed in laboratories may be upgraded to a new work cell configuration. This flexible approach allows laboratories to select a Beckman Coulter system with confidence, knowing they can adapt their system to changing work load requirements.

Beckman Coulter is the only instrument manufacturer to offer ClozCap™ technology—closed-tube sampling and aliquotting—which allows laboratories to eliminate labor-intensive de-capping, re-capping and sample splitting steps, increasing lab efficiency and operator safety. The systems also offer a comprehensive menu of more than 150 different tests, ranging from cardiac and tumor markers to tests for renal function, diabetes and more.

"Work cells are the fastest growing segment of the chemistry market and bring valuable workflow benefits to a laboratory. With our complete menu of tests and five different analyzers to choose from, our customers can find an integrated system that meets their needs. Plus, our variety of work cells means our customers have five price points to choose from, versus the competition's one or two. These important product introductions should allow us to complete our fourth record year of chemistry placements and continue our decade of above-market growth in the immunoassay market," said Atkin.

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company's 2007 annual revenue of $2.76 billion. For more information, including a copy of this release, visit the company's website at www.beckmancoulter.com.